Abstract 3207: TIM-3 expression in human cancer: A tissue microarray study on 17,172 patients

Abstract TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is an inhibitory immune checkpoint molecule which mainly occurs in subsets of inflammatory cells. On the surface membrane of cancer cells TIM-3 may represent a druggable target. To assess the prevalence of TIM-3 expression in cancer, a tissue microarray containing 17, 172 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry (IHC). TIM-3 expression of tumor cells and macrophages were semiquantitatively recorded. In cancer cells, a membranous TIM-3 positivity was predominantly seen in clear cell (61.9%) and papillary (62.5%) renal cell carcinomas (RCCs) but - less commonly - also in Hodgkin’s (25.0%) and non-Hodgkin’s lymphomas (up to 9.1%), epithelial thymomas (6.9%), ovarian carcinomas (0.7%-1.4%), seminomas (0.4%), and several mesenchymal neoplasms (up to 16.0%). High TIM-3 expression of tumor cells was linked to low grade (p=0.0079), low UICC stage (p=0.0085), low pT (p<0.0001), and pN0 (p=0.0067) in clear cell RCC (ccRCC), and to pM0 (p=0.0177) in papillary RCC (pRCC). TIM-3 expression of macrophages occurred in all tumor entities but its relationship with parameters of aggressive disease varied between entities. A high quantity of TIM-3 positive macrophages was linked to unfavorable tumor parameters such as high grade (p<0.0001), advanced pT stage (p=0.0126), and distant metastasis (p=0.0069) in ccRCC, as well as high grade (p<0.0001), HER2 positivity (p=0.0015), and absence of estrogen (p<0.0001) and progesterone receptor (p=0.0187) expression in invasive breast carcinomas of no special type. A high number of TIM-3 positive macrophages was linked to favorable tumor parameters such as L0 (p=0.0333) and V0 (p=0.0161) in mismatch repair protein proficient colorectal carcinoma, low pT (p=0.0128), L0 (p=0.0333), and V0 (p=0.0161), as well as a lack of rete testis (p=0.0053) and spermatic cord infiltration (p=0.0365) in testicular seminoma. It is concluded that tumor cell TIM-3 expression among epithelial or mesenchymal tumors is largely restricted to RCCs where high expression is associated with parameters of non-aggressive disease. TIM-3 expression in tumor associated macrophages is abundant and its clinical significance varies between tumor entities. Citation Format: Maximilian Lennartz, David Dum, Christian Bernreuther, Patrick Lebok, Guido Sauter, Andreas H Marx, Ronald Simon, Christoph Fraune, Natalia Gorbokon, Eike Burandt, Sarah Minner, Stefan Steurer, Till S Clauditz, Till Krech. TIM-3 expression in human cancer: A tissue microarray study on 17, 172 patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3207.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1538-7445.am2025-3207
Primary Topic
Galectins and Cancer Biology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3207: TIM-3 expression in human cancer: A tissue microarray study on 17,172 patients

Katharina Möller, Maximilian Lennartz, Guido Sauter, Lisa Hornsteiner et al.
Cancer Research
Galectins and Cancer Biology
article

Abstract 3207: TIM-3 expression in human cancer: A tissue microarray study on 17,172 patients

Katharina Möller, Maximilian Lennartz, Guido Sauter, Lisa Hornsteiner, Anne Menz, Florian Lutz, Eike Burandt, Andreas Marx, Stefan Steurer, Natalia Gorbokon, Christoph Fraune, Şeyma Büyücek, Christian Bernreuther, Till Krech, Andreas M. Luebke, Sarah Jane Pauline Minner, Viktor Reiswich, Claudia Hube‐Magg, Sören Weidemann, Elena Bady, Patrick Lebok, Frank Jacobsen, Florian Viehweger, Till Sebastian Clauditz, Ahmed Abdulwahab Bawahab, Ronald Simon, Andrea Hinsch, David Dum, Ria Schlichter, Sam Etebar Farimani
article en

Abstract

Abstract TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is an inhibitory immune checkpoint molecule which mainly occurs in subsets of inflammatory cells. On the surface membrane of cancer cells TIM-3 may represent a druggable target. To assess the prevalence of TIM-3 expression in cancer, a tissue microarray containing 17, 172 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry (IHC). TIM-3 expression of tumor cells and macrophages were semiquantitatively recorded. In cancer cells, a membranous TIM-3 positivity was predominantly seen in clear cell (61.9%) and papillary (62.5%) renal cell carcinomas (RCCs) but - less commonly - also in Hodgkin’s (25.0%) and non-Hodgkin’s lymphomas (up to 9.1%), epithelial thymomas (6.9%), ovarian carcinomas (0.7%-1.4%), seminomas (0.4%), and several mesenchymal neoplasms (up to 16.0%). High TIM-3 expression of tumor cells was linked to low grade (p=0.0079), low UICC stage (p=0.0085), low pT (p<0.0001), and pN0 (p=0.0067) in clear cell RCC (ccRCC), and to pM0 (p=0.0177) in papillary RCC (pRCC). TIM-3 expression of macrophages occurred in all tumor entities but its relationship with parameters of aggressive disease varied between entities. A high quantity of TIM-3 positive macrophages was linked to unfavorable tumor parameters such as high grade (p<0.0001), advanced pT stage (p=0.0126), and distant metastasis (p=0.0069) in ccRCC, as well as high grade (p<0.0001), HER2 positivity (p=0.0015), and absence of estrogen (p<0.0001) and progesterone receptor (p=0.0187) expression in invasive breast carcinomas of no special type. A high number of TIM-3 positive macrophages was linked to favorable tumor parameters such as L0 (p=0.0333) and V0 (p=0.0161) in mismatch repair protein proficient colorectal carcinoma, low pT (p=0.0128), L0 (p=0.0333), and V0 (p=0.0161), as well as a lack of rete testis (p=0.0053) and spermatic cord infiltration (p=0.0365) in testicular seminoma. It is concluded that tumor cell TIM-3 expression among epithelial or mesenchymal tumors is largely restricted to RCCs where high expression is associated with parameters of non-aggressive disease. TIM-3 expression in tumor associated macrophages is abundant and its clinical significance varies between tumor entities. Citation Format: Maximilian Lennartz, David Dum, Christian Bernreuther, Patrick Lebok, Guido Sauter, Andreas H Marx, Ronald Simon, Christoph Fraune, Natalia Gorbokon, Eike Burandt, Sarah Minner, Stefan Steurer, Till S Clauditz, Till Krech. TIM-3 expression in human cancer: A tissue microarray study on 17, 172 patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3207.

Cancer ResearchVol. 85(8_Supplement_1)
Universität Hamburg (DE), University of Jeddah (SA), University Medical Center Hamburg-Eppendorf (DE)
Openalex Percentile: Top 91%
Galectins and Cancer Biology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.